• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFR14A filed by Trevena Inc.

    5/3/24 4:06:32 PM ET
    $TRVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TRVN alert in real time by email
    DEFR14A 1 tm2413482d1_defr14a.htm DEFR14A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

     

    INFORMATION REQUIRED IN PROXY STATEMENT

    SCHEDULE 14A INFORMATION

     

    Proxy Statement Pursuant to Section 14(a) of

    the Securities Exchange Act of 1934

     

     (Amendment No. 1)

     

    Filed by the Registrant x

     

    Filed by a Party other than the Registrant ¨

     

    Check the appropriate box:

     

    ¨ Preliminary Proxy Statement
       
    ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
       
    ¨ Definitive Proxy Statement
       
    x Definitive Additional Materials
       
    ¨ Soliciting Material under §240.14a-12

      

    Trevena, Inc.

    (Name of Registrant as Specified In Its Charter)

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

     

    x No fee required.
       
    ¨ Fee paid previously with preliminary materials.
       
    ¨ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This amendment (this “Amendment”) dated May 3, 2024, amends and supplements the definitive proxy statement (the “Proxy Statement”) filed by Trevena, Inc., a Delaware corporation (the “Company”), with the Securities and Exchange Commission on April 29, 2024, for the Company’s Annual Meeting of Stockholders (the “Annual Meeting”) to be held on June 13, 2024, at 8:30 a.m. Eastern Time.

     

    This Amendment is being filed for the purpose of correcting the voting standard with respect to Proposal 5 – Approval of an amendment to our Amended and Restated Certificate of Incorporation (as amended, the “Restated Certificate”) to effect a reverse stock split of our outstanding shares of common stock by a ratio of any whole number between 1-for-2 and 1-for-25 (the “Reverse Stock Split”), at any time prior to August 28, 2024, with the exact ratio to be set within that range at the discretion of our Board of Directors, without further approval or authorization of our stockholders (“Proposal 5”) in the Proxy Statement, and to clarify the impact of abstentions and broker non-votes on the outcome of the vote on Proposal 5.

     

    Proposal 5 requires an affirmative vote representing a majority of the votes cast in person or represented by proxy and entitled to vote on the proposal instead of an affirmative vote of a majority of the shares outstanding and entitled to vote on the proposal. Abstentions and broker non-votes, if any, are not treated as votes cast, and therefore will have no effect on the outcome of the vote on Proposal 5.

     

    This Amendment hereby amends the Proxy Statement as follows:

     

    ·The row regarding Proposal 5 in the table on page 3 of the Proxy Statement under the section entitled “Questions and Answers About the Annual Meeting and Voting” shall read as follows:

     

    Proposal
    Number
    Summary Description Vote Required for
    Approval
    Effect of
    Abstentions
    Effect of
    Broker Non-
    Votes
    5

    Approval of an amendment to our Amended and Restated Certificate of Incorporation (as amended, the “Restated Certificate”) to effect a reverse stock split of our outstanding shares of common stock by a ratio of any whole number between 1-for-2 and 1-for-25 (the “Reverse Stock Split”), at any time prior to August 28, 2024, with the exact ratio to be set within that range at the discretion of our Board of Directors, without further approval or authorization of our stockholders. 

    Majority of votes cast No effect Not voted/No effect

     

    ·The first paragraph on page 39 of the Proxy Statement shall read as follows:

     

    Approval of this Proposal 5 requires “FOR” votes from the holders of a majority of the votes cast, either in person or represented by proxy, and entitled to vote at the Annual Meeting. If you “ABSTAIN” from voting, it will have no effect on the outcome of the vote on this Proposal 5.​ Broker non-votes, if any, will not count as votes cast and will have no effect on the outcome of the vote on this Proposal 5.

     

     

     

     

    ·The paragraph on page 45 of the Proxy Statement under the section entitled “Vote Required” shall read as follows:

     

    Approval of this Proposal 5 requires “FOR” votes from the holders of a majority of the votes cast, either in person or represented by proxy, and entitled to vote at the Annual Meeting. If you “ABSTAIN” from voting, it will have no effect on the outcome of the vote on this Proposal 5.​ Broker non-votes, if any, will not count as votes cast and will have no effect on the outcome of the vote on this Proposal 5.

     

    Except as specifically amended or supplemented by the information contained herein, this Amendment does not revise or update any other information set forth in the Proxy Statement. This Amendment does not provide all of the information that is important to your voting decisions at the Annual Meeting, and the Proxy Statement contains other important additional information. This Amendment should be read in conjunction with the Proxy Statement, and the Proxy Statement should be read in its entirety.

     

    If you have already returned your proxy card or provided voting instructions, you do not need to take any action unless you wish to change your vote. If you have submitted a proxy card and wish to change your vote, you may revoke your proxy and change your vote by following the instructions in the section entitled “Questions and Answers About the Annual Meeting and Voting – Can I change my vote?” of the Proxy Statement. This Amendment does not change the proposals to be acted upon at the Annual Meeting, which are described in the Proxy Statement.

     

     

     

    Get the next $TRVN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TRVN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TRVN
    SEC Filings

    View All

    Trevena Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - TREVENA INC (0001429560) (Filer)

    5/15/25 8:09:22 AM ET
    $TRVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 25-NSE filed by Trevena Inc.

    25-NSE - TREVENA INC (0001429560) (Subject)

    4/8/25 9:20:54 AM ET
    $TRVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form NT 10-K filed by Trevena Inc.

    NT 10-K - TREVENA INC (0001429560) (Filer)

    3/31/25 4:01:19 PM ET
    $TRVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRVN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Trevena Reports Third Quarter 2024 Results and Provides Business Update

    CHESTERBROOK, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the third quarter ended September 30, 2024 and provided an overview of its recent operational updates. Third Quarter 2024 and Recent Corporate Updates $2 million Non-Dilutive Financing Tranche. In July 2024, the Company announced receipt of a non-dilutive, $2 million tranche in connection with an amendment (the "Amendment") to its existing ex-US royalty financing with R-Bridge Healthcare Fund ("R-Bridge"). The Compa

    11/7/24 7:01:00 AM ET
    $TRVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Trevena Announces Receipt of Nasdaq Delisting Notification

    CHESTERBROOK, Pa., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that on October 4, 2024 the Company received notice that the Nasdaq Hearings Panel (the "Panel") had determined to delist the Company's common stock from The Nasdaq Stock Market LLC ("Nasdaq") due to the Company's failure to comply with the minimum stockholder's equity requirement under Nasdaq Listing Rule 5550(b)(1) (the "Equity Standard Rule"). As previously disclosed, the Panel had provided the Company until October 2, 2024, to regain comp

    10/4/24 4:05:00 PM ET
    $TRVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Trevena Announces Reverse Stock Split

    CHESTERBROOK, Pa., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has filed a Certificate of Amendment to its Certificate of Incorporation (the "Amendment") to effect a reverse stock split of its common stock at a ratio of 1-for-25. The reverse stock split will become effective at 12:01 a.m. ET on Tuesday, August 13, 2024. Trevena's common stock will continue to be traded on the Nasdaq Capital Market under the symbol "TRVN" and will begin trading on a split-adjusted basis when the market opens on Tu

    8/8/24 4:05:00 PM ET
    $TRVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Sutton Katrine claimed ownership of 942 shares (SEC Form 3)

    3 - TREVENA INC (0001429560) (Issuer)

    12/6/24 4:39:03 PM ET
    $TRVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acting CMO Demitrack Mark covered exercise/tax liability with 885 shares, decreasing direct ownership by 7% to 11,363 units (SEC Form 4)

    4 - TREVENA INC (0001429560) (Issuer)

    10/10/24 5:08:47 PM ET
    $TRVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acting COO and CFO Shin Barry covered exercise/tax liability with 806 shares, decreasing direct ownership by 7% to 11,543 units (SEC Form 4)

    4 - TREVENA INC (0001429560) (Issuer)

    10/10/24 5:07:55 PM ET
    $TRVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer initiated coverage on Trevena

    Oppenheimer initiated coverage of Trevena with a rating of Market Perform

    3/15/21 7:02:03 AM ET
    $TRVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Trevana

    Oppenheimer initiated coverage of Trevana with a rating of Perform

    3/15/21 6:50:29 AM ET
    $TRVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRVN
    Leadership Updates

    Live Leadership Updates

    View All

    Trevena, Inc. Appoints Mark Corrigan, M.D. to Board of Directors

    CHESTERBROOK, Pa. , July 20, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Mark Corrigan, M.D. has been appointed to the Company's Board of Directors, effective July 18 2023. "We are pleased to welcome Mark to Trevena's Board of Directors," said Carrie Bourdow, Trevena's President and CEO. "Mark has over 30 years of experience in the life sciences industry and broad neuroscience expertise. He will be an invaluable member of the Board and guide to the management team as we continue to execute on our corporate

    7/20/23 7:00:00 AM ET
    $TRVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Imvax Appoints John M. Limongelli as Chief Legal Officer

    Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, announced the appointment of John M. Limongelli as the Company's Chief Legal Officer effective September 16, 2021. "John's breadth of experience in the biopharma industry, his deep technical acumen, and his expertise at helping build strong corporate practices will be of invaluable benefit to our leadership team," said John Furey, Chief Executive Officer. "As we work to expand our platform to address a variety of solid tumors, John's expertise will be an essential part of the development of these assets." Mr. Limongelli is an accomplished executive officer and lawyer with near

    9/16/21 8:00:00 AM ET
    $TRVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRVN
    Financials

    Live finance-specific insights

    View All

    Trevena Reports Third Quarter 2023 Results and Provides Business Update

    Company previously announced statistically significant topline TRV045 data from two proof-of-concept studies evaluating S1PR mechanism of action and CNS target engagement Company reported favorable safety and tolerability data from TRV045 POC studies Three abstracts for OLINVYK presented at American Society of Anesthesiologists (ASA) Conference $15 million tranche from ex-US royalty-based financing agreement received in September Company to host conference call today, November 14, 2023 at 8:00 a.m. ET CHESTERBROOK, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for pat

    11/14/23 7:00:00 AM ET
    $TRVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Trevena to Release Third Quarter 2023 Financial Results on November 14, 2023

    CHESTERBROOK, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial results for the third quarter ended September 30, 2023, prior to the market open on Tuesday, November 14, 2023. The Company will host a conference call and webcast with the investment community at 8:00 a.m. ET that same day, featuring remarks by Carrie Bourdow, President and Chief Executive Officer, Mark Demitrack, M.D., SVP and Chief Medical Officer, and Barry Shin, SVP and Chief Financial Office

    11/9/23 7:00:00 AM ET
    $TRVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Trevena Announces Receipt of $15 Million Non-Dilutive Tranche and Provides General Business Update

    $15 million tranche from ex-US royalty-based financing, triggered by first commercial sale of OLINVYK by Jiangsu Nhwa, Trevena's partner in China New OLINVYK respiratory data from VOLITION ~200 patient real-world outcomes study, using continuous respiratory monitoring, expected 3Q 2023 Three OLINVYK abstracts accepted for presentation at upcoming American Society of Anesthesiologists Meeting in 4Q 2023 Company to participate in upcoming HC Wainwright conference (September 11-13) Company to Hold Conference Call on Wednesday, September 6 at 8 a.m. Eastern Time to discuss TRV045 Proof-of-Concept Data CHESTERBROOK, Pa., Sept. 06, 2023 (GLOBE NEWSWI

    9/6/23 7:01:00 AM ET
    $TRVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Trevena Inc.

    SC 13G/A - TREVENA INC (0001429560) (Subject)

    11/14/24 4:43:11 PM ET
    $TRVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Trevena Inc.

    SC 13G - TREVENA INC (0001429560) (Subject)

    9/19/24 4:09:55 PM ET
    $TRVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Trevena Inc. (Amendment)

    SC 13G/A - TREVENA INC (0001429560) (Subject)

    2/14/24 2:34:30 PM ET
    $TRVN
    Biotechnology: Pharmaceutical Preparations
    Health Care